

Table 1: The diseases, modalities, and indication categories for therapeutic apheresis procedures performed between June 2016 and July 2018 that were included in the study.

Diseases	Patient No	Modality Type	Sessions No	Indication category
Hematological diseases/disorders	57			
TTP	25	TPE	313	I
Hyperleukocytosis (acute/chronic leukemias)	13/7	Leukocytapheresis	118	III/ undefined
TMA (diarrhea +/-complement mediated)	6 (4/2)	TPE	31	III(5)/IV(1)
Hyperviscosity (MM/WM)	4 (2/2)	TPE	33	I
Aplastic anemia	1	TPE	3	III
HELLP (postpartum)	1	TPE	3	III
Nephrological diseases	23			
ANCA-associated vasculitis	10	TPE	60	I
Antibody-mediated rejection	6	TPE	18	I
FSGS (post-transplantation/steroid resistant nephrotic syndrome with hyperlipidemia)	5 (3/2)	TPE/DFPP	21/4	I(3)/III(2)
Cast nephropathy (MM)	1	TPE	3	II
Scleroderma renal crisis	1	TPE	5	III
Endocrinology and metabolism diseases	11			
FH	11	DFPP/IA	18/81	II
Neurological diseases	1			
Neuromyelitis optica	1	IA	2	II
Sepsis with multiorgan failure	3	TPE	6	III
Malaria	1	ErythrocyteExchange	1	III
Total	96		720	

No: number, TTP: thrombotic thrombocytopenic purpura, TMA: thrombotic microangiopathy, HELLP: hemolysis, elevated liver enzymes, and a low platelet count, ANCA: antinuclear cytoplasmic antibody, FSGS: focal segmental glomerulosclerosis, MM: multiple myeloma, WM: Waldenstrom macroglobulinemia, FH: Familial hyperlipidemias, TPE: therapeutic plasma exchange, DFPP: double filtration plasmapheresis, IA: immunadsorption.